Nucleic Acid Delivery with Biological and Synthetic Lipid Nanoparticles

Wednesday, 3 April 2024 at 17:30

Add to Calendar ▼2024-04-03 17:30:002024-04-03 18:30:00Europe/LondonNucleic Acid Delivery with Biological and Synthetic Lipid NanoparticlesExtracellular Vesicles (EVs) and Nanoparticles 2024: Diagnostics, Delivery, Therapeutics in Miami, FloridaMiami, FloridaSELECTBIOenquiries@selectbiosciences.com

Nucleic acid nanomedicines gain momentum. Starting with Onpattro, delivering siRNA to the liver and followed by the local injection of COVID mRNA vaccines, we currently witness an avalanche of new therapeutic applications. Following the same lipid nanoparticle recipe as Onpattro and the vaccines, enzyme replacement therapy for rare metabolic disorders in the liver and CRISPR mRNA/sgRNA combinations for hepatic gene editing are being explored clinically, amongst many others. For other applications in new tissues, this recipe needs to be tweaked. In this lecture, applications to spleen targeting, heart delivery and immune cell targeting will be discussed, and biological and synthetic systems are compared.

Raymond Schiffelers, Professor of Nanomedicine, University Medical Center Utrecht

Raymond Schiffelers

Raymond Schiffelers studied Bio-Pharmaceutical Sciences at Leiden University (1990-1995). After an industrial traineeship at SmithKline Beecham Pharmaceuticals (UK) he did his PhD in medical microbiology at Erasmus University Rotterdam on liposomal targeting of antimicrobial agents (1996-2001). Subsequently he became post-doc at Utrecht University working on liposomes targeting tumor vasculature. In 2002-2003, at Intradigm Co (USA) he expanded his tumor vasculature-targeting work with polymers for delivery of siRNA. After his return to Utrecht University he became assistant and then associate professor. He received an ERC Consolidator Grant in 2010 to investigate extracellular vesicles as biological drug delivery systems. After he moved to University Medical Center Utrecht in 2011 he became professor of nanomedicine working on bio-inspired and synthetic drug delivery systems. He coordinates two H2020 projects on this topic, B-SMART and EXPERT, is editor for the International Journal of Pharmaceutics, Journal of Controlled Release and Journal of Extracellular Vesicles, and is founder of EXCYTEX-an extracellular vesicle-based company. Since 2021 he also works part-time for Nanocell Therapeutics as VP Preclinical R&D and is president of the ETPN.